A Study to Assess the Effects of Bempedoic Acid in Patients with or at high risk for Cardiovascular DiseaseStatus: open
17-108 - A Randomized, Double-Blind, Placebo-Controlled study to Assess the Effects of Bempedoic Acid (ETC-1002) on the occurrence of Major Cardiovascular Events in Patients with, or at High Risk for Cardiovascular Disease who are Statin-Intolerant
Treatment for Cardiovascular Disease
The primary objective is to evaluate whether administration of bempedoic acid 180 mg/day versus placebo reduces the risk of MACE in patients with, or at high risk for, CVD who are statin intolerant. This will be assessed with a composite primary efficacy endpoint that includes time to first occurrence of CV death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina, or coronary revascularization. IRB Number 17-108
SponsorsThis trial is sponsored by Esperion Therapeutics, Inc..
Interested in Clinical Trial?
Providers Associated With This Trial
- Bassam A. Omar, M.D., Ph.D., F.A.C.C.CardiologistFellowship Director of Cardiovascular Diseases; Professor of Internal Medicine
- Michael V. Cohen, M.D.CardiologistProfessor of Physiology and Cell Biology
- Ghulam Mustafa Awan, M.D.Interventional CardiologistDirector of Interventional Cardiology and Endovascular Interventions; Associate Professor of Internal Medicine
- Christopher M. Malozzi, D.O.CardiologistAssistant Professor of Internal Medicine